Navigation Links
Baseline characteristics of children with mild persistent asthma predict response to ICS

ATS 2012, SAN FRANCISCO A further analysis of a previously published National Heart, Lung, and Blood Institute (NHLBI) funded study of children with mild persistent asthma reports the relative benefits of inhaled corticosteroid (ICS) treatment varies among children with differing demographic and clinical characteristics.

"We performed post-hoc data analysis on 288 children enrolled in the TReating Children to Prevent Exacerbations of Asthma (TREXA) study performed by the NHLBI funded Childhood Asthma Research and Education (CARE) Network," said Lynn Gerald, PhD, MSPH, professor in the Department of Health Promotion Sciences and associate dean of research in the College of Public Health at the University of Arizona. "Our findings suggest that all children with mild persistent asthma benefit from ICS treatment, but some groups benefit more than others."

The TREXA trial compared four ICS treatment strategies: daily treatment (daily), daily treatment plus symptom-targeted treatment (combined), symptom-targeted only treatment (rescue), and placebo. Daily treatment, but not combined or rescue treatment, reduced the time to first exacerbation compared with placebo, and all three strategies reduced treatment failures. Time to treatment failure was defined as time to an oral corticosteroid-requiring exacerbation and treatment failure was defined as experiencing two or more oral corticosteroid-requiring exacerbations.

In post-hoc subgroup analyses using either time to first exacerbation or time to treatment failure as an outcome, children in the daily and combined groups who were younger (6-11 yrs versus 12-17 years), were non-Hispanic, had eczema, were skin test positive, and who had IgE levels >185K/uL experienced treatment benefit as compared to those assigned to placebo. Among children assigned to the rescue group, the results were similar to those above when using time to treatment failure as an outcome; however, when using time to first exacerbation as an outcome, only those with eczema, high IgE levels, and less than perfect asthma control during the run-in period were demonstrated to benefit when compared to placebo.

"Our study indicates that some groups of children with mild persistent asthma have greater exacerbation risk than others and therefore have more to gain from ICS treatment for reducing this risk," said Dr. Gerald. "These findings need to be validated in future studies."


Contact: Nathaniel Dunford
American Thoracic Society

Related medicine news :

1. Baseline PSA predicts risk of death from prostate cancer
2. Early prostate cancer detection, screening: No benefit for men with low baseline PSA value
3. Does baseline concussion testing really reduce risks to athletes?
4. Validity of Baseline Concussion Tests Questioned
5. Concussion baseline important for accurate future assessment in at-risk youth athletes
6. Researchers find that sociodemographic characteristics are related to a patients willingness to participate in cancer screenings
7. Researchers report no difference in breast cancer characteristics after oophorectomy
8. Thesis investigates characteristics of society using sports activities as research tool
9. Why do risks with human characteristics make powerful consumers feel lucky?
10. New study helps clarify symptoms and characteristics of acid reflux in neonates
11. Pain characteristics suggest higher benefit from gallbladder surgery
Post Your Comments:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology: